(SQM) Sociedad Quimica y Minera - NYSE
Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: NYSE (USA) | Market Cap: 22.762m USD | Total Return: 114.9% in 12m
Avg Turnover: 99.5M
Qual. Beats: 0
Rev. Trend: -82.8%
Qual. Beats: 1
Warnings
Choppy Below Avwap Earnings
Tailwinds
Confidence
Sociedad Química y Minera de Chile S.A. (SQM) is a Chilean producer of specialty plant nutrients, iodine and its derivatives, lithium products, and industrial chemicals, with operations spanning Latin America, the Caribbean, Europe, North America, Asia, and other international markets. Its business is organized around four core segments: specialty plant nutrition, iodine, lithium, and industrial chemicals.
In specialty plant nutrition, SQM produces potassium nitrate, sodium nitrate, specialty blends, potassium sulfate, and potassium chloride, marketed under brands such as Ultrasol, Qrop, Speedfol, Allganic, Ultrasoline, Prop, and Prohydric. The iodine segment supplies medical, pharmaceutical, LCD/LED, and nutrition applications, including x-ray contrast media and iodized salt. The lithium segment produces lithium carbonate and lithium hydroxide for battery cathodes, alongside lithium chloride and derivatives used in glass, ceramics, and metal alloys. Industrial chemicals, including sodium nitrate, potassium nitrate, solar salts, and potassium chloride, serve glass, explosives, pyrotechnics, oil drilling, food processing, and solar power storage markets.
SQM was founded in 1926 and is headquartered in Santiago, Chile. As a large-cap Materials company in the Fertilizers & Agricultural Chemicals sub-industry, it derives its primary commercial advantage from natural resource extraction in the Chilean Atacama region, which holds some of the worlds highest-grade lithium and nitrate reserves.
- Lithium prices fall on Chinese EV demand slowdown
- Chile royalty reform caps long-term lithium margins
- Iodine and specialty plant nutrients revenue stabilizes earnings
| Net Income: 817.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 3.67 > 1.0 |
| NWC/Revenue: 83.73% < 20% (prev 81.52%; Δ 2.21% < -1%) |
| CFO/TA 0.12 > 3% & CFO 1.96b > Net Income 817.0m |
| Net Debt (1.32b) to EBITDA (1.85b): 0.71 < 3 |
| Current Ratio: 2.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (284.9m) vs 12m ago -0.25% < -2% |
| Gross Margin: 34.52% > 18% (prev 28.19%; Δ 6.33% > 0.5%) |
| Asset Turnover: 38.96% > 50% (prev 39.01%; Δ -0.05% > 0%) |
| Interest Coverage Ratio: 8.80 > 6 (EBIT TTM 1.62b / Interest Expense TTM 184.4m) |
| A: 0.28 (Total Current Assets 6.98b - Total Current Liabilities 2.53b) / Total Assets 15.8b |
| B: 0.26 (Retained Earnings 4.17b / Total Assets 15.8b) |
| C: 0.12 (EBIT TTM 1.62b / Avg Total Assets 13.6b) |
| D: 0.77 (Book Value of Equity 5.85b / Total Liabilities 7.56b) |
| Altman-Z'' = 4.32 = AA |
| DSRI: 1.49 (Receivables 1.07b/607.9m, Revenue 5.31b/4.48b) |
| GMI: 0.82 (GM 28.19% / 34.52%) |
| AQI: 1.87 (AQ_t 0.24 / AQ_t-1 0.13) |
| SGI: 1.19 (Revenue 5.31b / 4.48b) |
| TATA: -0.07 (NI 817.0m - CFO 1.96b) / TA 15.8b) |
| Beneish M = -2.14 (Cap -4..+1) = BB |
As of June 26, 2026, the stock is trading at USD 73.11 with a total of 1,079,637 shares traded. Over the past week, the price has changed by -11.91%, over one month by -9.10%, over three months by -6.97% and over the past year by +114.89%.
Current recommended Stop Loss: 66.20 (which is 9.5% or 2 ATR below the current price).
Sociedad Quimica y Minera has received a consensus analysts rating of 3.94. Therefore, it is recommended to buy SQM.
- StrongBuy: 6
- Buy: 4
- Hold: 5
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 82.6 | 13% |
P/E Trailing = 27.8636
P/E Forward = 11.6959
P/S = 4.295
P/B = 3.8896
P/EG = 0.3594
Revenue TTM = 5.31b USD
EBIT TTM = 1.62b USD
EBITDA TTM = 1.85b USD
Long Term Debt = 4.79b USD (from longTermDebt, last quarter)
Short Term Debt = 353.8m USD (from shortTermDebt, last quarter)
Debt = 5.18b USD (from shortLongTermDebtTotal, last quarter) + Leases 73.0m
Net Debt = 1.32b USD (calculated: Debt 5.18b - CCE 3.87b)
Enterprise Value = 24.1b USD (22.8b + Debt 5.18b - CCE 3.87b)
Interest Coverage Ratio = 8.80 (Ebit TTM 1.62b / Interest Expense TTM 184.4m)
EV/FCF = 22.32x (Enterprise Value 24.1b / FCF TTM 1.08b)
FCF Yield = 4.48% (FCF TTM 1.08b / Enterprise Value 24.1b)
FCF Margin = 20.31% (FCF TTM 1.08b / Revenue TTM 5.31b)
Net Margin = 15.38% (Net Income TTM 817.0m / Revenue TTM 5.31b)
Gross Margin = 34.52% ((Revenue TTM 5.31b - Cost of Revenue TTM 3.48b) / Revenue TTM)
Gross Margin QoQ = 44.23% (prev 34.10%)
Tobins Q-Ratio = 1.53 (Enterprise Value 24.1b / Total Assets 15.8b)
Interest Expense / Debt = 3.56% (Interest Expense 184.4m / Debt 5.18b)
Taxrate = 36.94% (531.5m / 1.44b)
NOPAT = 1.02b (EBIT 1.62b * (1 - 36.94%))
Current Ratio = 2.76 (Total Current Assets 6.98b / Total Current Liabilities 2.53b)
Debt / Equity = 0.89 (Debt 5.18b / totalStockholderEquity, last quarter 5.85b)
Debt / EBITDA = 0.71 (Net Debt 1.32b / EBITDA 1.85b)
Debt / FCF = 1.22 (Net Debt 1.32b / FCF TTM 1.08b)
Total Stockholder Equity = 5.60b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.99% (Net Income 817.0m / Total Assets 15.8b)
RoE = 14.59% (Net Income TTM 817.0m / Total Stockholder Equity 5.60b)
RoCE = 15.63% (EBIT 1.62b / Capital Employed (Equity 5.60b + L.T.Debt 4.79b))
RoIC = 7.67% (NOPAT 1.02b / Invested Capital 13.3b)
WACC = 8.41% (E(22.8b)/V(27.9b) * Re(9.81%) + D(5.18b)/V(27.9b) * Rd(3.56%) * (1-Tc(0.37)))
Discount Rate = 9.81% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -44.72 | Cagr: -0.16%
[DCF] Terminal Value 77.79% ; FCFF base≈793.0m ; Y1≈909.0m ; Y5≈1.34b
[DCF] Fair Price = 130.4 (EV 19.9b - Net Debt 1.32b = Equity 18.6b / Shares 142.8m; r=8.41% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.42 | # QB: 0
Revenue Correlation: -82.81 | Revenue CAGR: -24.65% | SUE: 1.59 | # QB: 1
EPS current Quarter (2026-06-30): EPS=2.09 | Chg30d=+30.00% | Revisions=+33% | Analysts=5
EPS next Quarter (2026-09-30): EPS=2.35 | Chg30d=+30.44% | Revisions=+20% | Analysts=4
EPS current Year (2026-12-31): EPS=6.56 | Chg30d=+15.77% | Revisions=+54% | GrowthEPS=+218.2% | GrowthRev=+72.3%
EPS next Year (2027-12-31): EPS=6.16 | Chg30d=+10.40% | Revisions=+38% | GrowthEPS=-6.0% | GrowthRev=-1.4%
[Analyst] Revisions Ratio: +54%